The CSF proteomic alterations observed in both Aβ+/tau+ and Aβ+/tau- AD patients using this workflow were highly consistent with findings generated by alternative proteomic workflows and mass spectrometry platforms. This evidence concerns the gene MAPT and Alzheimer disease.